ArticleLancet regional health. Americas2026
Dengue infection in kidney transplant recipients during a major epidemic and the implementation of systematic donor screening: a cohort study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During Brazil's unprecedented dengue epidemic in 2023-2025, we develop a rationale for organ donor screening to mitigate the risk of donor derived transmission using rapid, widely available, and low-cost tests. Here we aimed to describe the epidemiology, clinical presentation, and outcomes among kidney transplant recipients (KTRs) who developed different routes of dengue infection and establish a policy for mitigating the risk of donor transmission. Methods: This study conducted at a large kidney transplant center in Brazil-Hospital do Rim (HRIM) examined dengue in KTRs through three components: initial cases of donor-derived infection that led to systematic donor screening; donor screening and adjudication for potential transmission from August 2023 to April 2025; and outcomes of vector-borne dengue among recipients followed at HRIM from December 2023 to July 2024. Donors were screened using immunochromatographic NS1 antigen and IgM rapid tests, with RT-PCR for those NS1-negative and IgM-positive. Findings: Before August 2023, we recorded four donor-derived transmissions from two deceased donors, resulting in three deaths. After that, among 1252 deceased donors screened, eight were NS1-positive and four had clinical evidence of dengue; these 12 donors were excluded from donation. Among 58 NS1-negative/IgM-positive donors, 38 were considered for donation. From these, 52 recipients were transplanted, with no confirmed donor-derived transmission. Among 1542 recipients of kidneys from NS1- and IgM-negative donors, 17 developed dengue within 30 days after transplantation: one had fatal transfusion-transmitted dengue, two had confirmed donor-derived transmission, ten had potential donor-derived transmission, and four were considered to have vector-borne infection acquired before transplantation. Every recipient with confirmed or potential donor-derived transmission identified during the screened period recovered from the infection. Lastly, among 12,402 KTRs on follow-up, we recorded 373 confirmed vector-borne cases. They were 50·0 years old, 203 were male (54·4%), 170 were female (45·6%), and 232 were White (62·2%). The case-fatality rate was 1·88%, compared with 0·10% in the general population during the same period. Interpretation: KTRs with vector-borne dengue experienced a high observed case-fatality rate. Organ or blood transmission led to life-threatening outcomes. The rapid test screening was associated with low transmission, and when it occurred, the risk of severe cases was mitigated. These findings support the incorporation of dengue screening strategies in endemic regions. Funding: Fundação Oswaldo Ramos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.